EurekAlert!

SENIOR-RITA trial investigates the use of an invasive strategy to treat older patients after a NSTEMI

London, United Kingdom – 1 September 2024: An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older adults did not affect the combined ...
News Medical

Invasive strategy shows no benefit in cardiovascular death reduction for older NSTEMI patients

An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older adults did not affect the combined risk of cardiovascular death or MI, although ...
The Globe and Mail

Myocardial Infarction Pipeline Drugs Report 2025: Evaluating Cutting-Edge Therapies, Clinical Trial Milestones, Key Companies, and Emerging SMA Treatment Options

DelveInsight’s, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...
Mena FN

Myocardial Infarction Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approval By Delveinsight Faraday Pharma, Acticor Biotech, Boehringer ...

(MENAFN- GetNews) Myocardial Infarction pipeline constitutes 30+ key companies continuously working towards developing 40+ Myocardial Infarction treatment therapies, analysis of Clinical Trials, ...